Company Encyclopedia
View More
name
Rundu Pharma
002923.SZ
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, quality research, and registration of chemical drugs.
3.144 T
002923.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking200/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.73%D
    • Profit Margin-4.37%D
    • Gross Margin45.37%B
  • Growth ScoreD
    • Revenue YoY-2.76%D
    • Net Profit YoY-234.95%E
    • Total Assets YoY-4.26%D
    • Net Assets YoY-8.89%D
  • Cash ScoreD
    • Cash Flow Margin-2288.68%E
    • OCF YoY-2.76%D
  • Operating ScoreC
    • Turnover0.56C
  • Debt ScoreC
    • Gearing Ratio49.50%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rundu Pharma released its performance for the first three quarters, with a net loss attributable to the parent company of 54.6878 million yuan

    According to the Zhitong Finance APP, Rundu Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 884 million yuan, a year-on-year increase of 0.85%. The net loss attributable to shareholders of the listed company was 54.6878 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 66.1263 million yuan

    Zhitong·
    SZ
    002923
    -1.60%
    Zhitong·
    SZ
    002923
    -1.60%

    Rundu Pharma: Application for the listing of isosorbide mononitrate chemical raw materials has been approved

    According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Approval Notice for the Market Application of Isosorbide Mononitrate" issued by the National Medical Products Administration. This product is suitable for the long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; and in combination with digoxin and/or diuretics for the treatment of chronic congestive heart failure: treatment of pulmonary hypertension

    Zhitong·
    SZ
    002923
    -1.60%
    Zhitong·
    SZ
    002923
    -1.60%

    Rundu Pharma: Passed the on-site inspection by the European Medicines Agency

    Rundu Pharma announced that from May 14, 2025, to May 16, 2025, the company underwent an on-site GMP inspection of the active pharmaceutical ingredient CEP by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Recently, the company received the "Inspection Certificate" issued by EDQM, and the inspection was successfully passed

    Zhitong·
    SZ
    002923
    -1.60%
    Zhitong·
    SZ
    002923
    -1.60%

    Rundu Pharma: Valsartan Amlodipine Tablets (I) Obtains Drug Registration Certificate

    According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration, involving the drug: Valsartan and Amlodipine Tablets (I). This product is suitable for the treatment of primary hypertension. It is used for patients whose blood pressure cannot be adequately controlled with monotherapy

    Zhitong·
    SZ
    002923
    -1.60%
    Zhitong·
    SZ
    002923
    -1.60%

    Rundu Pharma: Net loss of 36.1931 million yuan in the first half of 2025

    Rundu Pharma announced that its operating revenue in the first half of 2025 was CNY 548 million, a year-on-year decrease of 8.22%. The net profit attributable to shareholders of the listed company was -CNY 36.1931 million, a year-on-year decrease of 195.75%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

    Zhitong·
    SZ
    002923
    -1.60%
    Zhitong·
    SZ
    002923
    -1.60%
    © 2025 Longbridge｜Disclaimer